Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

New Jersey, USA-based clinical-stage biotech Imunon has appointed Dr Douglas Faller as chief medical officer, effective 18, ...

In a statement on Friday, the USA’s National Institutes of Health (NIH) said it would cut grants for "indirect costs" related ...

Pliant Therapeutics, a Californian biopharma focused on discovering and developing fibrosis drugs, saw its shares close down ...

A new bill has been presented for a pilot scheme that will allow pharmaceutical companies in Denmark to negotiate ...

France-based biopharma company Medincell this morning revealed it is to receive a $5 million development milestone from ...

On Sunday night, one of the USA’s largest compounders, Hims & Hers, ran a multi-million dollar Super Bowl advert about its provision of GLP-1 weight loss medications.

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

The ORPHAN Cures Act (HR 946), a bipartisan bill that removes barriers to treating and curing rare diseases, was reintroduced in the US House of Representative last week.